

# Wyeth Pharmaceuticals Development Pipeline (as of October 16, 2008)

Wyeth's R&D pipeline includes novel candidate medicines across our three platforms—small molecules, vaccines, and biopharmaceuticals. Many of these candidate medicines have the potential to be first-in-class, best-in-class, and/or first-in-therapy. Our development portfolio of new candidate medicines from Development Track to Registration, shown by therapeutic area and indication, is outlined below. We also have a discovery portfolio of 200 different projects and therapeutic targets.

***The information shown below is current as of October 16, 2008. Changes occur frequently and we undertake no obligation to update this information.***

## Phase 0

### Cardiovascular

GAP-134 (Oral)

Atrial Fibrillation

### Infectious Disease

BLI-489 (IV)  
RAS-111 (IV)

Infectious Disease  
Sepsis

### Inflammation

ATN-103 (SC)  
ATR-107 (SC)  
ATR-107 (SC)  
ILV-095 (SC)  
SBI-087 (SC)

Rheumatoid Arthritis  
Crohn's Disease  
Lupus/Systemic Lupus Erythematosus (SLE)  
Psoriasis  
Lupus/Systemic Lupus Erythematosus (SLE)

### Musculoskeletal Disorders

BMP-655 (Implantable)  
diboterminalfa - CPM (Intraosseous)

Surgical Repair of Tendons  
Hip Osteoporosis

### Neuroscience

AAB-002 (IV)  
AAB-003 (IV)  
ACC-002 (IM)  
HTC-867 (Oral)  
ILS-920 (IV)  
MMS-255 (Oral)

Alzheimer's Disease  
Alzheimer's Disease  
Alzheimer's Disease  
Cognitive Impairment Associated with Schizophrenia  
Stroke  
Multiple Sclerosis

## Phase 1

### Cardiovascular

GAP-134 (IV)

Atrial Fibrillation

### Infectious Disease

ERB-257 (IV)

Sepsis

### Inflammation

ILV-094 (SC)

ILV-094 (SC)

IMA-026 (SC)

SBI-087 (SC)

Psoriasis

Rheumatoid Arthritis

Asthma

Rheumatoid Arthritis

### Metabolic

HSD-016 (Oral)

Diabetes

### Neuroscience

bapineuzumab (AAB-001) (SC)

GSI-136 (Oral)

GSI-953 (Oral)

NSA-789 (Oral)

NSA-789 (Oral)

PAZ-417 (Oral)

Alzheimer's Disease

Alzheimer's Disease

Alzheimer's Disease

Cognitive Impairment Associated with Schizophrenia

Alzheimer's Disease

Alzheimer's Disease

### Vaccines

MnB rLP2086 (IM)

Meningococcal Serogroup B (Infant)

### Women's Health

PRA-027 (Oral)

Uterine Fibroids

## Phase 2

### Infectious Disease

moxidectin (Oral Tablets)  
Tygacil® (tigecycline) (IV)

Onchocerciasis (River Blindness)  
Hospital-Acquired Pneumonia

### Inflammation

anrukinzumab (IMA-638) (SC)  
TRU-015 (IV)

Asthma  
Rheumatoid Arthritis

### Metabolic

Relistor® (methylnaltrexone bromide) (Oral)

Opioid-induced Constipation in Chronic Pain

### Musculoskeletal Disorders

diboterminalfa - CPM (PC)

Fracture Repair

### Neuroscience

ACC-001 (IM)  
Pristiq® (desvenlafaxine succinate) (Oral Tablets)  
Pristiq® (desvenlafaxine succinate) (Oral Tablets)  
SAM-531 (Oral)  
vabicaserin HCl (SCA-136) (SR Capsules)

Alzheimer's Disease  
Fibromyalgia  
Major Depressive Disorder (Pediatric)  
Alzheimer's Disease  
Schizophrenia

### Oncology

bosutinib (Oral)  
inotuzumab ozogamicin (IV)  
neratinib (Oral)

Breast Cancer Combination Therapy  
Diffuse Large B-cell Lymphoma / Non-Hodgkin's Lymphoma  
Breast Cancer

### Vaccines

MnB rLP2086 (IM)

Meningococcal Serogroup B (Adolescent)

## Phase 3

### Infectious Disease

Tygalil® (tigecycline) (IV)

Diabetic Foot Infection

### Metabolic

Protonix® (pantoprazole sodium) (IV, granules)

Gastrointestinal Reflux Disease (Pediatric)

### Neuroscience

bapineuzumab (AAB-001) (IV)

Alzheimer's Disease

### Oncology

bosutinib (Oral)

inotuzumab ozogamicin (IV)

Torisel® (temsirolimus) (IV)

Chronic Myelogenous Leukemia

Follicular Non-Hodgkin's Lymphoma

Renal Cell Carcinoma Combination Therapy

### Vaccines

13vPnC (IM)

13vPnC (IM)

Invasive Pneumococcal Disease (Adult)

Invasive Pneumococcal Disease (Infant)

### Women's Health

bazedoxifene/conjugated estrogens (Oral Tablets)

Menopausal Symptoms / Osteoporosis

## Submitted for Registration

### Hemophilia

BeneFIX® Coagulation Factor IX (Recombinant) (IV) Hemophilia B (Japan)

ReFacto® AF Coagulation Factor VIII (Recombinant) (IV) Hemophilia A (EU)

### Infectious Disease

Tygacil® (tigecycline) (IV)

Community-acquired Pneumonia

### Inflammation

Enbrel® (etanercept) (SC)

Juvenile Rheumatoid Arthritis (Japan)

### Oncology

Torisel® (temsirolimus) (IV)

Mantle Cell Lymphoma (EU)

Torisel® (temsirolimus) (IV)

Renal Cancer (Japan)

### Vaccines

Prevenar® (Pneumococcal 7-valent Conjugate  
Vaccine [Diphtheria CRM<sub>197</sub> Protein]) (SC)

Invasive Pneumococcal Disease (Infant) (Japan)

### Women's Health

Pristiq® (desvenlafaxine succinate) (Oral Tablets)

Menopausal Vasomotor Symptoms

Viviant™ (bazedoxifene) (Oral Tablets)

Osteoporosis

*The statements in this document that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, there can be no assurance that any of the candidate medicines identified above will be developed successfully into commercial products. Other risks and uncertainties that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property, and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions, including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q, and annual report on Form 10-K, particularly the discussion under the caption "Item 1a, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this document are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise.*

Please note: Trademarks for products that have not received final regulatory approval are subject to change.